Biogen Inc.

NASDAQ Global Select
Back to all articles
Somewhat Bearish -25

Biogen, Denali Say Parkinson's Drug Didn't Meet Trial Endpoints -- Update

📉 Biogen and Denali Therapeutics announced the discontinuation of further development for their Parkinson's drug BIIB122 due to failed trial results.

🧪 The Phase 2b clinical trial failed to meet its primary or secondary endpoints in slowing disease progression for early-stage Parkinson's patients.

👥 The study involved 648 participants aged 30 to 80 who received treatment for a duration ranging from 48 to 144 weeks.

💊 BIIB122 is an investigational small molecule inhibitor targeting LRRK2, a gene variant linked to Parkinson's disease pathology.

📉 Denali Therapeutics shares dropped 7% to $18 following the announcement of the trial failure.

📉 Biogen stock declined 1% to $187.49 in response to the negative clinical data update.

🔬 Despite the setback, Denali plans to continue conducting a Phase 2a study evaluating the inhibitor specifically in carriers of a pathogenic LRRK2 variant.

⚠️ The decision marks a significant pause for the partnership's efforts to treat idiopathic Parkinson's disease with this specific mechanism.

Bullish Signals
  • Denali Therapeutics will continue to conduct a Phase 2a study evaluating the small molecular inhibitor in carriers of a pathogenic LRRK2 variant, indicating ongoing research efforts despite the setback.
  • The drug BIIB122 targets LRRK2, a gene linked to Parkinson's disease, maintaining focus on a significant therapeutic area with potential future applications for specific patient subgroups.
Risk Factors
  • Biogen and Denali Therapeutics discontinued development of BIIB122 for idiopathic Parkinson's disease after the Phase 2b trial failed to meet primary or secondary endpoints.
  • The drug showed no ability to slow disease progression in a study involving 648 participants treated for up to 144 weeks.
  • Denali shares retreated 7% to $18 following the announcement of the clinical trial failure.
  • Biogen's stock declined 1% to $187.49, reflecting investor concern over the setback in their Parkinson's pipeline.
  • The failure of BIIB122, an LRRK2 inhibitor, suggests potential challenges for this therapeutic approach in treating early-stage Parkinson's disease.
  • Denali Therapeutics will only continue a Phase 2a study for carriers of a pathogenic LRRK2 variant, indicating the broader application for idiopathic Parkinson's was unsuccessful.
  • The discontinuation of BIIB122 development represents a significant setback for Biogen and Denali in their efforts to treat Parkinson's disease.
Full Analysis
Biogen and Denali Therapeutics announced the discontinuation of development for BIIB122, an investigational small molecule inhibitor targeting LRRK2 to treat idiopathic Parkinson's disease, after the Phase 2b trial failed to meet its primary or secondary endpoints. The study involved 648 participants aged 30 to 80 with early-stage Parkinson's who received treatment for a duration ranging from 48 to 144 weeks, but the drug did not demonstrate a significant slowing of disease progression. Following the announcement, Denali Therapeutics shares fell 7% to $18, while Biogen stock declined 1% to $187.49. Despite this setback for idiopathic Parkinson's, Denali plans to continue its Phase 2a study evaluating the same small molecule inhibitor specifically in carriers of a pathogenic LRRK2 variant, indicating a strategic pivot toward genetic subtypes of the disease rather than the broader population.